Slide 1: FY results 2024
FY results 2024 13 March 2025 These written materials or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registrati
Slide 2: Today's presenters
Today’s presenters Walter Hess Daniel Wüest CEO CFO | FY 2024 results 2
Slide 3: Agenda
Agenda 1. Business update 2. Financial update 3. Outlook 4. Q&A | FY 2024 results 3
Slide 4: Highlights 2024
Business update Highlights 2024 5x new Rx EBITDA 7% revenue TeleClinic CHF 95m customers yoy profitability growth doubled cash with achieved contribution revenues prudent cash significantly in non-Rx from all with strong management improved business businesses EBITDA KPIs | FY 2024 results 4
Slide 5: Driving DocMorris forward in 2025
Business update Driving DocMorris forward in 2025 Accelerating New Profitable TeleClinic Targeted Rx growth marketing growth to advance CHF 200m Very attractive campaign in non-Rx strong capital raise cohorts and “Mach´s dir growth to support unit Doc einfach” and scale Rx growth & economics profita
Slide 6: Further accelerated Rx revenue growth
Business update Further accelerated Rx revenue growth 2.5x EURm 2.5x 60 55 50 45 Strong growth of 40 GKV eRx revenues 35 30 25 ~50% 20 15 10 5 0 Q1 2024A Q2 Q3 Q4 Q1 2025E Rx growth in Q1 25 PKV pRx revenue1 GKV pRx revenue 2 eRx revenue expected 1 PKV = private Krankenversicherung (private health i
Slide 7: Continuous, strong new Rx customer growth
Business update Continuous, strong new Rx customer growth New Rx customers State-of-the-art apps with CardLink access 5x Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023A 2024A Indicative app displays | FY 2024 results 7
Slide 8: eRx customer loyalty and order frequency vastly improved since CardLink
Business update eRx customer loyalty and order frequency eRx insights vastly improved since CardLink eRx cohort reorder rate1 ~2.5x higher than pRx 2.00 ~2.5x pRx cohorts 57 eRx CardLink cohorts Average age 110 CardLink users EUR AOV2 1.00 85% 95% May-23 Jun-23 Jul-23 Aug-23 Sep-23 App / CardLink Ne
Slide 9: Non-Rx business DE reached profitability
Business update Non-Rx business DE reached profitability Profitable non-Rx DE business Value drivers · OTC/BPC margin improvement · Teleclinic, retail media and marketplace Profitable growth EBITDA non-Rx DE1 Performance improvements · Operational performance · Marketing performance Cost optimisatio
Slide 10: Mach's dir Doc einfach! campaign to boost eRx orders
Business update Mach‘s dir Doc einfach! campaign to boost eRx orders · Being top of mind and strengthen awareness of brand and CardLink solution · Leverage campaign with DocMorris “Mach´s dir Doc einfach”- song and TV · Increase consideration and conversion by aligning with performance initiatives ·
Slide 11: TeleClinic is uniquely positioned and has just started to scale
Business update TeleClinic is uniquely positioned and has just started to scale · Large untapped ~EUR 55bn1 ambulatory medical care market with <1% online penetration · Technological drivers2: eAU, eRx and ePA · Telemedicine platform with take rate model >2.5m App provides highly attractive margins
Slide 12: Strongest value proposition in Germany for patients, doctors and partners
Business update Strongest value proposition in Germany for patients, doctors and partners Exponential growth since 2021 Extensive network effects Continuously winning strong partners Treatments (k) Healthcare platforms for fully reimbursed treatments1 3,000 >3m Treatments FY24 Doctors (in million) (
Slide 13: Sustainability targets 2024 reached with big leap towards net zero
Business update Sustainability targets 2024 reached with big leap towards net zero Healthier people Sustainable Caring company Reliable planet partnerships · Five additional · Slight increase of health journeys · Switch to gender pay gap ~30% signed & new ingredient renewable to ~4% Supplier Code of
Slide 14: DocMorris: Your health companion... more than a pharmacy
Business update DocMorris: Your health companion... ...more than a pharmacy · Changing user behavior: from searching products to seeking health solutions eRx · Digitalization in healthcare: eRx, ePA, eAU etc. Tele- enable seamless digital health journeys leading OTC/BPC medicine to better adherence,
Slide 15: Agenda
Agenda 1. Business update 2. Financial update 3. Outlook 4. Q&A | FY 2024 results 15
Slide 16: Solid top-line growth, ongoing improvement of gross margin
Financial update Solid top-line growth, ongoing improvement of gross margin, while EBITDA mirroring increased marketing spend in Rx External revenue1 Adj. gross margin5 Adj. EBITDA & margin5 CHF m (7.4%)2 6.7%2 350 bps 50 bps (120 bps) · External revenue grew 6.7% in LC2 and 560 bps (120 bps) 4.6% i
Slide 17: Both segments, Germany and Europe, returned to sales growth
Financial update Both segments, Germany and Europe, returned to sales growth External revenue1 Adj. gross margin5 Adj. EBITDA & margin5 CHF m (7.1%)2 6.9%2 370 bps 60 bps · Revenue grew 6.9% in LC2 (4.8% in CHF) 510 bps (140 bps) while non-Rx grew 7.9% in LC and Rx 2.1% in LC despite negative H1 gro
Slide 18: Return to customer growth with typical pattern of initially lower KPIs
Financial update Return to customer growth with typical pattern of initially lower KPIs Active customers1 last 12 months (million) Site visits last 12 months (million) 10.3 195 195 10.0 185 9.1 Dec 2023 Jun 2024 Dec 2024 Dec 2023 Jun 2024 Dec 2024 Basket size2 in EUR Order frequency3 Repeat order ra
Slide 19: FY 2024: Operational expenses improved noticeably
Financial update FY 2024: Operational expenses improved noticeably Margin Margin FY yoy in CHF m FY 2024 FY 20231 in % in % in % External revenue2 1,085.0 1,037.5 4.6 External revenue2, in local currency 1,106.6 1,037.5 6.7 1,017.0 966.9 5.2 · External revenue grew by 6.7% in LC Consolidated revenue
Slide 20: Solid, asset-light balance sheet backed with CHF 95m of cash
Financial update Solid, asset-light balance sheet backed with CHF 95m of cash 31 Dec 31 Dec in CHF m % % 2024 2023 Cash and cash equivalents 95.4 54.0 Current financial assets 0.0 97.0 Receivables 78.4 79.2 Inventories 37.1 51.8 Property, plant & equipment · Asset-light balance sheet with a strong e
Slide 21: Continuous reduction of indirect costs and focus on NWC management
Financial update Continuous reduction of indirect costs and focus on NWC management Indirect cost margin Average net working capital margin (% of external revenue) (% of consolidated revenue) (30 bps) 30 bps · Substantial reduction of · Focus on active NWC3 (50 bps) indirect cost base in management
Slide 22: Agenda
Agenda 1. Business update 2. Financial update 3. Outlook 4. Q&A | FY 2024 results 22
Slide 23: Trading indication: Continuous growth across all businesses
Outlook Trading indication: Continuous growth across all businesses • Specified outlook to be provided in the context of the planned capital increase • Banks have been mandated for targeted capital increase of around CHF 200m, to • invest in new Rx customers over the next years; and • secure potenti
Slide 24: Agenda
Agenda 1. Business update 2. Financial update 3. Outlook 4. Q&A | FY 2024 results 24
Slide 25: © DocMorris SA
© DocMorris SA
Slide 26: Backup
Backup
Slide 27: Financial maturity and cash flow overview
Back-up Financial maturity and cash flow overview in CHF m H2 2023 H1 2024 H2 2024 Maturity profile as of 31 December 2024 Cash start of period 199.7 54.0 105.1 Operating cash flow (50.2) (11.1) (13.4) Coupon Financing cash flow (3.2) 191.9 (3.8) 3.0 % Investing cash flow (31.9) (6.7) 100.6 Conversi
Slide 28: Shareholder structure
Back-up Shareholder structure As of 12 March 2025 As of 31 December 2024 100% free float Shares 14,835,093 UBS Fund Management 5.61% Thereof own shares 3,018,581 Swisscanto Fondsleitung 3.06% Thereof share lending facility1 3,018,579 Lemanik Holding 3.03% Shares outstanding 11,816,512 Management as
Slide 29: Financial calendar
Back-up Financial calendar Date Event/Publication 13 March 2025 2024 FY Results and Outlook 2025 (incl. conference call) 10 April 2025 Q1 2025 Trading Update & invitation to AGM with details for targeted capital increase 8 May 2025 Annual General Meeting 2025 19 August 2025 H1 2025 Results (incl. co
Slide 30: Thank you
Thank you
Slide 31: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by DocMorris AG ("DocMorris" and together with article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") its subsidiaries, "we", "us" or "DocMorris") solely for informational purpose